Profile data is unavailable for this security.
About the company
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.
- Revenue in USD (TTM)60.28m
- Net income in USD-113.87m
- Incorporated2014
- Employees449.00
- LocationAdaptimmune Therapeutics PLC60 Jubilee Avenue, Milton ParkABINGDON OX14 4RXUnited KingdomGBR
- Phone+44 123 543 0000
- Websitehttps://www.adaptimmune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | 192.64m | 2.51m | 265.82m | 203.00 | 105.36 | 0.4878 | 48.17 | 1.38 | 0.0439 | 0.0439 | 3.35 | 9.47 | 0.3004 | 11.60 | 5.69 | 948,965.50 | 0.3912 | 6.61 | 0.4547 | 7.62 | 92.32 | 90.55 | 1.30 | 15.18 | 4.92 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Monte Rosa Therapeutics Inc | 0.00 | -135.35m | 267.32m | 133.00 | -- | 1.49 | -- | -- | -2.64 | -2.64 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -41.90 | -- | -47.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 832.01k | -135.12m | 267.73m | 122.00 | -- | 2.05 | -- | 321.79 | -6.12 | -6.12 | 0.0375 | 5.15 | 0.0032 | -- | 0.9778 | 6,819.75 | -52.02 | -59.52 | -71.11 | -71.29 | -- | -- | -16,239.87 | -4,097.36 | -- | -- | 0.125 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| ESSA Pharma Inc | 0.00 | -25.80m | 268.97m | 50.00 | -- | 1.91 | -- | -- | -0.5851 | -0.5851 | 0.00 | 3.19 | 0.00 | -- | -- | 0.00 | -16.68 | -23.01 | -17.03 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Inozyme Pharma Inc | 0.00 | -71.17m | 274.27m | 59.00 | -- | 1.95 | -- | -- | -1.39 | -1.39 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -41.86 | -45.00 | -45.82 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2417 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Avenue Therapeutics Inc | 0.00 | -10.38m | 274.42m | 3.00 | -- | 1.34 | -- | -- | -133.23 | -133.23 | 0.00 | 4.64 | 0.00 | -- | -- | 0.00 | -241.24 | -186.91 | -382.29 | -287.70 | -- | -- | -- | -- | -- | -70.24 | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
| Adaptimmune Therapeutics PLC - ADR | 60.28m | -113.87m | 274.73m | 449.00 | -- | 6.18 | -- | 4.56 | -0.5218 | -0.5218 | 0.2995 | 0.1739 | 0.1972 | -- | 14.60 | 134,256.10 | -37.24 | -41.19 | -48.02 | -48.21 | -- | -- | -188.90 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| Ventyx Biosciences Inc | 0.00 | -192.96m | 276.78m | 79.00 | -- | 0.9544 | -- | -- | -3.29 | -3.29 | 0.00 | 4.12 | 0.00 | -- | -- | 0.00 | -59.46 | -- | -63.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Sanara Medtech Inc | 64.99m | -4.30m | 278.95m | 107.00 | -- | 6.16 | -- | 4.29 | -0.5219 | -0.5219 | 7.85 | 5.25 | 0.9635 | 1.90 | 8.37 | 607,381.70 | -6.58 | -17.73 | -8.17 | -22.07 | 87.92 | 88.08 | -6.83 | -17.13 | 1.04 | -18.75 | 0.1786 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Akebia Therapeutics Inc | 194.62m | -51.93m | 280.56m | 167.00 | -- | -- | -- | 1.44 | -0.2778 | -0.2778 | 1.04 | -0.1572 | 0.6512 | 2.22 | 4.89 | 1,165,407.00 | -17.37 | -37.42 | -28.19 | -56.00 | 78.76 | 69.13 | -26.68 | -82.25 | 1.03 | -7.64 | 8.46 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Zura Bio Ltd | 0.00 | -69.24m | 280.85m | 14.00 | -- | 3.24 | -- | -- | -4.38 | -4.38 | 0.00 | 1.36 | 0.00 | -- | -- | 0.00 | -49.98 | -- | -60.56 | -- | -- | -- | -- | -- | -- | -- | 0.0123 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -116.80m | 281.88m | 131.00 | -- | 1.89 | -- | -- | -3.05 | -3.05 | 0.00 | 4.27 | 0.00 | -- | -- | 0.00 | -53.15 | -46.30 | -57.90 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Lyra Therapeutics Inc | 1.56m | -62.68m | 281.99m | 88.00 | -- | 3.02 | -- | 180.99 | -1.32 | -1.32 | 0.0313 | 1.56 | 0.0123 | -- | -- | 17,704.54 | -49.63 | -58.01 | -57.37 | -68.69 | -- | -- | -4,023.11 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Metagenomi Inc | 44.76m | -68.26m | 282.17m | 236.00 | -- | -- | -- | 6.30 | -1.82 | -1.82 | 1.19 | 5.73 | -- | -- | -- | 189,644.10 | -- | -- | -- | -- | -- | -- | -152.50 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -43.16m | 282.47m | 40.00 | -- | 2.08 | -- | -- | -0.5357 | -0.5357 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -29.12 | -40.04 | -31.88 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Adaptimmune Therapeutics PLC's reporting currency: US Dollar USD
52.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Matrix Capital Management Co. LPas of 31 Dec 2023 | 38.97m | 15.79% |
| EcoR1 Capital, LLCas of 08 Mar 2024 | 27.40m | 11.10% |
| Baillie Gifford & Co.as of 31 Dec 2023 | 15.91m | 6.45% |
| Long Focus Capital Management LLCas of 31 Dec 2023 | 12.09m | 4.90% |
| Baker Bros. Advisors LPas of 31 Dec 2023 | 10.97m | 4.44% |
| PFM Health Sciences LPas of 31 Dec 2023 | 10.42m | 4.22% |
| Bank of America, NA (Private Banking)as of 31 Dec 2023 | 4.66m | 1.89% |
| Tang Capital Management LLCas of 31 Dec 2023 | 4.39m | 1.78% |
| Citadel Advisors LLCas of 31 Dec 2023 | 3.10m | 1.25% |
| Rock Springs Capital Management LPas of 31 Dec 2023 | 2.43m | 0.98% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
